Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.

We cover:

• Can moisturizing infants prevent atopic dermatitis?
• New sunscreen ingredients headed for the US market
• Insights from lichenoid eruptions linked to immune checkpoint inhibitors
• What to do if oral JAKs fail in alopecia areata
• Does CeraVe outperform other moisturizers?
• The real risk of cardiovascular and thromboembolic events with JAK inhibitors
• Why IL-13 inhibitors differ in likelihood of causing arthralgias
• Advances in autologous skin cell transplantation for vitiligo
• The safety of patients self-injecting triamcinolone for acne
• New findings on hypersensitivity reactions after sentinel lymph node biopsy
• Can patch testing help with burning mouth syndrome?
• A drug that reduces cardiovascular mortality in hidradenitis suppurativa
• Novel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosis
  

Join us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.
Listen now and stay ahead in dermatology!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling all kinds of medical diseases - whether we're talking about patients who can't access (or don't respond adequately) to our highly effective FDA approved drugs for psoriasis, atopic dermatitis, alopecia areata, hidradenitis or about patients with diseases that don't have an extremely effective FDA approved drug - things like lichen planus, granuloma annulare, dermatitis herpetiformis and many, many more.  This week, we talk through dapsone, roflumilast, and acitretin.
In this episode, you’ll learn:

Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.
Tune in for clinical pearls and expert insights you can put to work in your practice!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.
In this episode, you’ll learn:
--When and why to reach for these time-tested therapies in real-world practice
--How to monitor labs and counsel patients for safety and success
--Tips for discussing off-label treatments and navigating complex cases
Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.
Tune in for clinical pearls and expert insights you can put to work in your practice!
Article titles:
1.  Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial
2.  Lower Oncogenic Risk with Dermatologic Use of Mycophenolate Mofetil Compared to Transplant Prophylaxis: A Retrospective Study
3.  Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Today on Derms on Drugs we’ve got the fabulous Dr. Heather Woolery-Lloyd with us, and yes—we’re talking sunscreens. Don’t roll your eyes, because we’re going way past “SPF 30 or 50?” into the good stuff: how these lotions and potions actually work, which myths need to finally get buried, and why tinted sunscreens aren’t just makeup but legit medicine for skin of color.

We’ll also dish on the brand-new Aussie rules for UV protection and spill which brands actually look good on darker skin without turning you into a ghost.

And because no episode is complete without it, we’ll detour into lifestyle hacks, chat a little nutrition, and finish with our usual trivia shenanigans.

So, grab your SPF (tinted or not, we don’t judge), and let’s dive in"

Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!

What’s on Tap in Our 6 Pack Episode?

Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:

• New Therapy for Recessive Dystrophic Epidermolysis Bullosa: We’re walking through the latest clinical trial that could be a real gamechanger.
• Homemade vs. Commercial Sunscreens: Should your patients blend SPF cocktails in the kitchen, or is that a recipe for disaster?
• Immunosuppressives and Patch Testing: Just how “immunosuppressed” can your patients be and still get valid patch testing results? We’ve got the hottest updates from the experts—no immuno-anxiety required.
• HPV Vaccine vs. Actinic Keratoses: A blockbuster therapy for warty issues? This clinical trial investigates the HPV vax as a new weapon in the fight against actinic keratoses.
• Hailey-Hailey Disease Treatment Algorithms: Confused by this rare disease? We’re breaking down shiny new algorithms so you can manage it like a pro.
• JAK Inhibitor Discontinuation and Heart Risks: Why do patients sometimes trade clear skin for cardiac drama after stopping a JAK inhibitor? The science just got spicier, and we’ve got the scoop.

So scrub in, sit back, and let us put the “fun” in fundamentals as we break down the latest, greatest (and occasionally weirdest) in the world of clinical dermatology. Let’s pop open that six-pack and get started.

And for links to all of the articles we discussed in this episode, visit ScholarsInMedicine.com

Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:

• Review three of the hottest papers on bullous pemphigoid, dissecting the latest evidence with our signature blend of rigor and irreverence.
• Break down the recent FDA approval of dupilumab for bullous pemphigoid—a new kid on the blister block!
• Unpack the pivotal dupilumab study results, then pit them against real-world evidence. Does the hype hold up outside the ivory tower?
• Debate how we’ll actually integrate dupilumab into our clinical arsenal. Is this a game-changer or just another tool in the kit?
• Explore the real impact on patient care: Will this approval mean fewer steroids, better outcomes, or simply more options for those tough-to-treat cases?
• Refresher course in bullous pemphigoid - diagnosis and practical treatment pearls

So, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.

For Links to articles please go to ScholarsinMedicine.com

1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era

2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study

3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:

• Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?

• Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.

• The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.

Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.

Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.
We break down the newest literature and answer:
Does immunotherapy really help with high-risk squamous cell carcinoma?
Are pemphigus patients getting more rituximab than they need?
Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?
Is the Mind.Px test actually helpful for picking a psoriasis biologic?
What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?
Which treatment factors predict scabies cure?
Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!
Hit play and stay on the cutting edge of medical dermatology!

1.  Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma
2.  Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
3.  Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium
4.  Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
5.  Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
6.  Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab
7.  Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:

-How Dupixent is changing the game for CSU and why dermatologists are leading the charge

-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients

-How we explain to CSU patients that they don’t need allergy testing!

-Clinical pearls for work-up, navigating treatment guidelines, safety, and access

Perfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.

Hit play and stay ahead on the cutting edge of CSU care!

1.  Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound

2.  Remibrutinib in Chronic Spontaneous Urticaria

3.  Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.

This week, we break down:

• Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis

• The future of autoimmune disease treatment: genetically modified T cells

• What policies people actually support (and will pay for) to reduce skin cancer rates

• JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for

• The latest on rising contact allergens: which ones are on the move and why

Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.

Don’t miss out—hit play for your weekly dose of dermatology insights!

For links to all articles visit ScholarsinMedicine.com

1.  Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2.  Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3.  Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4.  Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5.  Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6.  Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022